Storia in 3 fonti

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)

Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.

Raccontata da

endpoints.news

fiercepharma.com

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 g fa

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)

Eli Lilly announces BRUIN CLL-322 success: Jaypirca added to venetoclax and rituximab reduces progression-or-death risk by 45% in relapsed or refractory CLL/SLL. The company plans to seek regulatory label expansion and pursue additional Phase 3 trials, extending therapeutic options for patients with prior BTK-inhibitor exposure.

originale

fiercepharma.com1 g fa

Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data

Jaypirca + venetoclax-rituximab cut CLL progression/death risk by 45.3%; second-line post-BTK patients gained 67.7% PFS benefit (BRUIN CLL-322). Strong efficacy with low toxicity reshapes BTK inhibitor market dynamics and biotech M&A strategy for oncology-focused acquirers.

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)

Confronto fonti

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)

Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data

Timeline cronologica

Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data

Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)